Lv51
990 积分 2023-07-28 加入
Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2
9天前
已关闭
Simple hysterectomy with pelvic lymphadenectomy versus radical hysterectomy with pelvic lymphadenectomy for women with stage IA2-IB1 cervical cancer
1个月前
已关闭
Biomarkers in High-Grade Serous Ovarian Cancer: Context is everything
1个月前
已完结
Simple hysterectomy with pelvic lymphadenectomy versus radical hysterectomy with pelvic lymphadenectomy for women with stage IA2-IB1 cervical cancer
1个月前
已关闭
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer
1个月前
已完结
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
1个月前
已完结
328 RENI-1: a prospective, multicenter real-world study of niraparib as first-line maintenance therapy in newly diagnosed advanced ovarian cancer
1个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
1个月前
已完结
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial
1个月前
已完结
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
